Regen BioPharma, Inc. (RGBP)
OTCMKTS
· Delayed Price · Currency is USD
0.0004
-0.0001 (-20.00%)
Apr 29, 2026, 3:07 PM EST
Regen BioPharma Revenue
Regen BioPharma had revenue of $59.07K in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to $236.56K, up 0.00% year-over-year. In the fiscal year ending September 30, 2025, Regen BioPharma had annual revenue of $236.56K with 0.00% growth.
Revenue
236.56K
Revenue Growth
+0.00%
P/S Ratio
0.51
Revenue / Employee
236.56K
Employees
1
Market Cap
120.88K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 236.56K | 1.00 | 0.00% |
| Sep 30, 2024 | 236.56K | - | - |
| Sep 30, 2023 | 236.56K | 1.04K | 0.44% |
| Sep 30, 2022 | 235.52K | 64.32K | 37.57% |
| Sep 30, 2021 | 171.19K | 61.19K | 55.63% |
| Sep 30, 2020 | Pro | Pro | Pro |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Helix BioMedix | 2.07M |
| Lipella Pharmaceuticals | 389.78K |
| THC Farmaceuticals | 18.52K |
| CNBX Pharmaceuticals | 40.64K |
| Sorrento Therapeutics | 64.27M |
| Endonovo Therapeutics | 255.72K |
Regen BioPharma News
- 6 months ago - Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. - Accesswire
- 1 year ago - Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ - GlobeNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time - GlobeNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024 - PRNewsWire